Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Coherus BioSciences, Inc. (Nasdaq: CHRS) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Positive
- None.
Negative
- None.
REDWOOD CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that senior management will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:45 a.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/upcoming-events. This webcast will be available for replay until February 9, 2024.
Coherus Contact Information:
Jami Taylor, Head of Investor Relations
Coherus Biosciences, Inc.
IR@coherus.com
Coherus BioSciences, Inc. will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:45 a.m. Pacific Time.
The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website.
The webcast will be available for replay until February 9, 2024.
The contact person is Jami Taylor, Head of Investor Relations, and the email is IR@coherus.com.
Coherus BioSciences, Inc.
NASDAQ:CHRS
CHRS Rankings
CHRS Latest News
Apr 24, 2024
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 8, 2024
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
CHRS Stock Data
222.46M
103.90M
1.35%
77.99%
20.8%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
REDWOOD CITY
About CHRS
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp